NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01296503,Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma,https://clinicaltrials.gov/study/NCT01296503,,COMPLETED,"This multicenter, prospective, randomized trial was designed to evaluate the role of thalidomide with or without dexamethasone as a maintenance therapy for multiple myeloma patients after a single autologous stem cell transplantation.",NO,Multiple Myeloma,DRUG: Thalidomide plus dexamethasone|DRUG: Dexamethasone,"Progression Free survival, Primary endpoint: progression free survival (PFS) PFS was defined as the time between randomization and any documentation of relapse, progression, or death by any cause., 36 months","Overall survival, Secondary endpoints: overall survival (OS) was defined as the interval from randomization to death (or the last follow-up for surviving patients). For patients who were not randomized, OS was calculated from the date of diagnosis until the date of death or last follow-up., 36 months|safety of thalidomide, The number of patients experiencing adverse events grade 3 or 4 were compared between treatment arms. Adverse events were classified as defined by the National Cancer Institute Common Toxicity Criteria, version 2. Safety evaluations were focused especially on neurological symptoms and the development of deep venous thrombosis (DVT). Adverse events evaluations were performed at the time of response assessment and whenever a new clinical manifestation suggestive of toxicity appeared., 36 months",,Grupo de Estudos Multicentricos em Onco-Hematologia,,ALL,"ADULT, OLDER_ADULT",PHASE3,213,NETWORK,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,GBRAM0001,2003-10,2008-07,2010-12,2011-02-15,,2011-02-15,"Universidade Estadual de Campinas, Campinas, São Paulo, Brazil|Universidade de São Paulo- Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil|Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, 21941913, Brazil|Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil",
